Business Wire

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in the Treatment of Acute Myeloid Leukemia

CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...
FierceBiotech

FDA grants humanitarian use for Miltenyi's stem cell transplant device

Miltenyi Biotec announced today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, ...
Labroots

Leveraging Recent Advances in Miltenyi's Cell Sorting Automation Platforms to Reduce Time to Data in Primary Cell-Based Assays.

This seminar will give attendees a full overview of two new Miltenyi cell sorting platforms, the MultiMACS X and the CliniMACS Prodigy and how these instruments can be used in various primary cell ...
Business Today

Miltenyi Biotec establishes first India office and CGT Center in Hyderabad

Miltenyi Biotec opens first office and Technology Center in Hyderabad, India, focusing on Cell and Gene Therapy (CGT). The Center offers training, research, and manufacturing solutions for CGT, using ...
PR Newswire

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in the Treatment of Acute Myeloid Leukemia

Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- ...
Europa Press

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in

CliniMACS(R) CD34 Reagent System approved as a Humanitarian Use Device authorized by U.S. Federal law Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the ...